Translational Development Acquisition, ProLogium to Combine in $3.8 Billion Transaction

MT Newswires Live
05/27

Translational Development Acquisition (TDAC), a blank-check company, and ProLogium said Wednesday they have agreed to a business combination valuing ProLogium at about $3.8 billion on a pre-money, net cash-free basis.

ProLogium will seek funding by a combination of Translational's cash in trust and proceeds from a private investment in public equity deal, the companies said.

The boards of both companies have approved the deal, which is set to close in H2 and would result in the combined company ProLogium Technology becoming a Nasdaq-listed company under the ticker symbol PRLG, according to the statement.

The transaction is anticipated to fund the scaling of ProLogium's production of its fourth-generation batteries and the construction of a gigafactory in Dunkirk, France, the companies said.

ProLogium aims to mass produce solid-state battery technology with its proprietary lithium ceramic battery platform, the companies added.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10